Failure in DNA elongation predicts sensitivity to camptothecin in the colon cell lines of the NCI anticancer drug screen

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 308-309

  Goldwasser, François ^a,b   Shimizu, Tsunehiro ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN;

CANCER CELL CULTURE; CELL LINE; CONFERENCE PAPER; DNA REPLICATION; DRUG SCREENING; HUMAN; HUMAN CELL;

EID: 0030467447     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26401.x     Document Type: Conference Paper

References (5)

1. GUPTA, M., A. FUJIMORI & Y. POMMIER. 1995. Eukaryotic DNA topoisomerase I. Bioch. Biophys. Acta 1262: 1-14.
2. GOLDWASSER, F., M. VALENTI, R. TORRES & Y. POMMIER. 1996. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin. Clin. Cancer Res. 2: 687-693.
3. CHEN, A. Y. & L. F. LIU. 1994. DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 94: 194-218.
4. POMMIER, Y., F. LETEURTRE, M. FESEN, A. FUJIMORI, R. BERTRAND, E. SOLARY, G. KOLHAGEN & K. W. KOHN. 1994. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12: 530-542.
5. GOLDWASSER, F., I. BAE, M. VALENTI, K. TORRES & Y. POMMIER. 1995. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer Screen. Cancer Res. 55: 2116-2121.